The recently updated World Health Organization (WHO) Classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML. Despite the progress in unraveling the tumor genome, only a small number of recurrent mutations have been incorporated into risk-stratification schemes and have been proven to be clinically relevant, targetable lesions. We here discuss the utility of molecular markers in AML in prognostication and treatment decision making, specifically highlighting the aberrations included in the current WHO classification.
| INTRODUC TI ON
In acute myeloid leukemia (AML), recurrent cytogenetic abnormalities are established diagnostic and prognostic markers, suggesting that acquired genetic abnormalities play an essential role in leukemogenesis. 1 The prognosis for patients with AML is determined to a large degree by the biology of the disease. Roughly 45% of the patients harbor a normal karyotype as detected by conventional cytogenetics at diagnosis, yet a somatic mutation can be identified in 97.3% of the cases. 2 Targeted sequencing has identified several mutations that carry prognostic information, including mutations in FLT3, NPM1, KIT, CEBPA, and TET2. 3 In addition, massively parallel sequencing led to the discovery of recurrent mutations in DNMT3A
and IDH. 4, 5 The recently updated World Health Organization (WHO) classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of AML has led to remarkable advances in our understanding of the disease. 5 Currently, the WHO classification includes eight AML categories defined by recurrent genetic abnormalities (including AML with t(9;22)(q34;q11.2)/BCR-ABL1 as a provisional entity) as well as three categories defined by gene mutations, that is, AML with NPM1, AML with biallelic mutated CEBPA, and the provisional entity AML with mutated RUNX1. Consistently, AMLs defined by recurrent genetic abnormalities are associated with distinctive clinicopathological features and impact prognosis. AML with FLT3, however, is not included as a separate entity, because it occurs across multiple subtypes.
However, the WHO classification acknowledges that FLT3 should be tested in all AML cases. 5 Although new molecular analysis techniques, such as ultra-deep sequencing, has helped to identify numerous recurrent genetic abnormalities, to date, however, only a limited number have been incorporated into risk-stratification schemes, such as the National
Comprehensive Cancer Network or European LeukemiaNet (ELN)
Guidelines (Table 1) . 6 In addition, increasing evidence indicates that the presence of minimal residual disease (MRD), measured either molecularly or by multiparameter flow cytometry, identifies patients at particularly high risk of relapse and provides powerful prognostic information beyond pretreatment characteristics such as cytogenetic or molecular abnormalities. 7 Nonetheless, in adult AML MRD as a tool to fine-tune risk assessment during postremission therapy with adaption of treatment strategy is lagging behind acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), or chronic myeloid leukemia (CML), in which MRD is now routinely used to guide treatment decisions at predefined checkpoints during therapy. [8] [9] [10] [11] [12] Here, we review genetic abnormalities that should be used for treatment stratification in AML and their clinical implications.
| CORE-B IND ING FAC TOR LEUK EMIA
In this category, AMLs characterized by the balanced translocation t(8;21)(q22;q22.1) and with the pericentric inversion inv (16) (p13.1q22) or the less frequent balanced translocation t(16;16) (p13.1;q22) are grouped and considered as AML regardless of bone marrow blast cell counts at diagnosis. 6 Both t(8;21), involving RUNX1-RUNX1T1, and inv(16)/t(16;16), involving CBFB-MYH11, harbor chimeric fusions involving genes of the core-binding factor (CBF) complex, a major regulator of hematopoiesis, providing the common designation CBF-AML. Patients with CBF-AML are considered to have a favorable prognosis as compared to other genetic risk groups. 13 After an anthracycline-and cytarabine-based induction chemotherapy, about 90% of CBF-AML patients achieve a complete remission (CR) 14, 15 and repeated cycles of postremission chemotherapy with high-dose cytarabine (HiDAC) (usually 3-4) have emerged as preferred treatment of CBF-AML. [16] [17] [18] The relapse risk may not exceed 20-35% in 3-5 years with repeated courses of intensive consolidation therapy. 15, [19] [20] [21] [22] Consequently, these patients have, on average, no survival advantage with allogeneic stem cell transplantation (allo-SCT) while in first remission because the transplant-related mortality is greater than the decrease in relapse rates afforded by the transplant. 23, 24 Recently published data from the Medical Research Council (MRC) AML15 trial in younger adult patients with favorable-risk AML indicated an improved survival after therapy with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-Ida) followed by two cycles of HiDAC consolidation with an 8-year survival rate of 95%. 25 In addition, the combination of gemtuzumab ozogamicin (GO) with chemotherapy has been shown to improve overall survival (OS) in subgroup analysis of CBF-AML, [26] [27] [28] suggesting that higher intensity regimens may lead to deeper log reductions after the first course of chemotherapy as has been shown for the addition of GO to intensive chemotherapy 20 as well as for anthracycline dose intensification during intensive induction chemotherapy. 29 Patients who received daunorubicin of 90 mg/m² showed a faster and deeper MRD reduction and achieved a higher proportion of complete molecular responses (at least 3 log reduction as compared to diagnosis as measured by real-time quantitative polymerase chain reaction 13 Defined by the presence of one single monosomy (excluding loss of X or Y) in association with at least one additional monosomy or structural chromosome abnormality (excluding core-binding factor AML).
(RT-qPCR) with at least 10 −4 sensitivity) that translated into a reduced relapse rate as compared to those patients receiving 60 mg/ m². As a consequence, the combination of FLAG-GO (GO 3 mg/m 2 intravenously on day 1 during induction and two of six postremission cycles) has been evaluated as front-line therapy in 45 younger adult patients (median age, 48 years) with CBF-AML. 30 This regimen resulted in a high CR rate of 95% with 5% induction deaths.
The OS and relapse-free survival (RFS) probability at 3 years were 78% and 85%, respectively, suggesting that a deeper molecular remission could be achieved as compared to the standard HiDAC 
| ACUTE PROMYELO C Y TI C LEUK EMIA
Acute promyelocytic leukemia (APL) with the balanced translocation t(15;17)(q22;q12) involving PML-RARA accounts for 5-8% of AML cases with a lower incidence in elderly patients and is considered as AML regardless of bone marrow blast cell counts at diagnosis. 6 In APL, molecular assessment of disease response has become standard practice, and MRD-directed therapy quite plausibly improves outcome, particularly in patients with high-risk disease.
41,42
The chemotherapy-free regimen with arsenic trioxide and all-trans retinoic acid has proven to be highly effective in de novo APL and has become standard first-line therapy in younger adult, non-high- 
| AML WITH t (6;9) (p23;q3 .1)/D EK-N U P214
The translocation t(6;9)(p23;q34.1), which results in formation of the DEK-NUP214 chimeric fusion gene, was first described in AML in 1976 53 and acts as an aberrant transcription factor. 54 It alters the nuclear transport by binding soluble transport factors 55 and has been reported to enhance protein synthesis in myeloid cells. 56, 57 In AML, t(6;9) accounts for only a very small subgroup (1-2%) and has been associated with a poor prognosis with 5-year OS rates of 28% reported in children and only 9% in adults. 58 Overall, outcome in both pediatric and adult AML with t(6;9) is poor [58] [59] [60] [61] [62] and adult patients with this translocation are assigned to the adverse-risk group. 13 Of note, up to 90% of AML patients with t(6;9) are described to harbor a concomitant FLT3-ITD, [58] [59] [60] 58 or have not found a significant adverse impact.
60,61
However, allo-SCT may improve survival if applied early during first CR. 58, 64 In a matched-pair analysis of de novo AML using data from the Japanese allo-SCT data registry, the outcome of 57 patients with t(6;9) was compared to that of 171 patients with normal karyotype. 64 All patients received an allo-SCT between 1996 and 2007, either in first or second CR (CR1 and CR2, n = 116), or as salvage therapy (n = 112). In this matched-pair analysis in patients with t(6;9), the 5-year OS (45% vs 40%), disease-free survival (42% vs 33%), cumulative incidence of relapse (42 vs 45%), and non-relapse mortality (16% vs 22%) were not different as compared to normal karyotype AML. 64 In addition, we have recently evaluated the impact of allo-SCT on outcome in n = 123 adult patients with t(6;9)
in a large, international collaborative analysis. 65 In our cohort, we observed a high CR rate of 79% including sixteen patients, who required an intensive salvage treatment cycle with HiDAC. Five-year OS rates after allo-SCT (n = 51) were very encouraging (55% vs 18%; P < 0.001) as compared to patients who received consolidation chemotherapy (n = 44) regardless of FLT3-ITD status, additional cytogenetic abnormalities, or timing of transplant. These results suggest that allo-SCT may overcome the adverse impact of t(6;9) in AML patients, rendering outcome comparable to patients with normal cytogenetics.
| AML WITH inv (3)(q21 . 3 q26 . 2) OR t (3;3) (q21 . 3;q26 . 2); GATA 2, MECOM
AML with inv(3) or t(3;3) accounts for 1-2% of all AML and occurs most commonly in adults. 6 AML with inv(3)/t(3;3) is most frequently associated with monosomy 7 or complex karyotype (≥3 chromosomal abnormalities in the absence of one of the WHO designated recurring translocations or inversions) and confers an unfavorable outcome. 66 Genetically, inv(3)/t(3;3)
involves MECOM (also termed EVI1) at 3q26.2 and repositions the GATA2 enhancer to activate MECOM expression, thereby inducing GATA2 haploinsufficiency. 67 Gröschel et al 68 showed
that 98% of inv(3)/t(3;3) myeloid malignancies harbor mutations in genes activating RAS/receptor tyrosine kinase (RTK) signaling pathways. This high incidence of RAS/RTK signaling pathways may provide a target for a rational treatment strategy in this high-risk patient group. In addition, the authors could show that hemizygous mutations in GATA2, as well as heterozygous alterations in RUNX1, SF3B1, and genes encoding epigenetic modifiers, frequently co-occur with inv(3)/t(3;3) aberrations. 68 Within their analysis, neither mutational patterns nor gene expression profiles differed across inv(3)/t(3;3) AML, CML, or myelodysplastic syndrome cases. The authors therefore suggested that inv(3)/t(3;3) myeloid malignancies should be regarded as a single disease entity irrespective of blast count. 68 From a clinical aspect, however, there is currently no specific treatment available that has shown convincing improvement of outcome of this high-risk disease with only about one-third of patients with inv(3)(t(3;3) achieving a CR despite intensive induction therapy and few, if any, long-term survivors. 66 Thus, investigational therapy within a clinical trial should be considered in these patients, whenever possible.
| AML (MEG AK ARYOB L A S TI C) WITH t (1;22) (p13 . 3;q13 .1)/RB M15-MKL1
Acute megakaryoblastic leukemia (AMKL) with t( 
| AML WITH BCR-AB L1
BCR-ABL1-mutated AML again is a rare subtype (<1%) that is now included as a provisional entity in the current WHO classification. 6 Since a clear distinction between de novo BCR-ABL-mutated AML and CML in blast crisis is challenging in many cases, the existence of de novo BCR-ABL-mutated AML has been a matter of debate for a long time. However, increasing evidence suggests that BCR-ABLmutated AML is in fact a distinct subgroup of AML. 82, 83 Preliminary data suggest that deletion of antigen receptor genes (immunoglobulin heavy chain and T-cell receptor), IKZF1, and/or CDKN2A may support a diagnosis of AML rather than CML blast phase. 84 The prognosis of BCR-ABL-mutated AML seems to depend on the cytogenetic and/or molecular background rather than on BCR-ABL itself. 84 A therapy with tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib is reasonable, 85 but their use cannot be routinely recommended in first-line therapy due to a lack of systematic clinical data. However, intensive chemotherapy in combination with TKI 86, 87 and/or as a bridge to allo-SCT seems to be a feasible approach.
| AML WITH G ENE MUTATI ON S

| AML with mutated NPM1
Frameshift mutations of the NPM1 gene are one of the most frequent molecular abnormalities in AML, particularly in patients with a normal karyotype 88 with a high incidence in both young and older AML patients. [89] [90] [91] NPM1 mutations result in cytoplasmic accumulation, regulating the ARF-p53 tumor suppressor pathway, thus controlling proliferation and apoptosis. 92 In contrast to other molecular aberrations (eg, FLT3), NPM1 mutations are typically stable during the course of the disease, which supports the notion that they are an early pathogenetic lesion in AML. 93 To date, more than 50 different NPM1 mutations have been reported; however, the subtypes A, B, and D comprise 90% of all variants. 94 These three mutation subtypes have been shown to be reliable markers for MRD detection with high sensitivity. 7, 95 The same assay can be adapted for cases with rare NPM1 mutation variants by replacing mutation-specific primers, but case-specific RT-qPCRs need to be carefully established to avoid non-specific background amplification from the wild-type NPM1 allele. 96 Concurrent mutations occur typically in FLT3, DNMT3A, IDH1/2, or TET2. 88 In several studies, it has been shown that the prognostic impact of NPM1 should be interpreted in the context of a cooperating FLT3-ITD mutation, which is present in approximately 45% of this patient population with normal karyotype. [97] [98] [99] In particular, in younger adult NPM1-mutated patients with high FLT3-ITD allelic ratio (≥0.5) 13,100-102 the favorable prognostic effect of NPM1 is mitigated or even abolished as compared to patients with a low allelic ratio. 21, 101, 102 In comparison, patients with mutated NPM1 without FLT3-ITD or FLT3-ITD with a low allelic ratio (< 0.5) are associated with a somewhat better outcome. 13, 102 These data have recently been confirmed in a large cohort of intensively treated adult AML patients. 103 However, in patients with Similar to the findings in CBF-AML, RT-qPCR assessment of MRD can distinguish patients at high risk of relapse: In a study on 245 adult patients with NPM1-mutated AML, relevant MRD checkpoints could be defined. 106 Achievement of RT-qPCR negativity after two courses of induction therapy identified patients with a low CIR (6.5% after 4 years) as compared to RT-qPCR-positive patients (53% after 4 years; P < 0.001), translating into significant differences in OS (90% vs 51%, respectively; P = 0.001). After completion of therapy, CIR was 15.7% in RT-qPCR-negative patients as compared to 66.5% in RT-qPCR-positive patients (P < 0.001). 106 These data are extended by the study of Hubmann et al 107 in whom a NPM1 mutation cutoff level of 0.01 after induction therapy as measured by RT-qPCR (with a sensitivity of 10
) was associated with a CIR after 2 years of 77.8% for patients with ratios above as compared to Regarding the prognostic impact, concurrent TET2 mutations were associated with an unfavorable impact on OS as compared to TET2 wild-type patients (P = 0.035), whereas GATA2 mutations had a favorable impact (P = 0.032). The favorable prognostic impact of biallelic mutated CEBPA gets lost in the presence of FLT3-ITD. 119, 120, 122 Given the high CR rate after reinduction therapy in younger adult relapsed AML patients with biallelic mutated CEBPA of 83% (n = 35/42) and favorable outcome after allo-SCT in CR2, 123 we recommend HiDAC-based consolidation chemotherapy in patients with biallelic mutated CEBPA in CR1.
| AML with mutated RUNX1
The Runt-related transcription factor 1 (RUNX1) gene encodes a transcription factor critical for hematopoiesis and was associated with embryonic lethality in a murine model. 124 In AML, RUNX1 mutations have been reported to occur with an incidence of 5.6%15 to 13.2%, 125 predominantly in patients with intermediate-risk cytogenetics. In patients with cytogenetically normal AML, the incidence seems to increase with higher age, with an incidence of 8% in younger patients compared with 16% in older patients. 126 Interestingly, RUNX1 mutations are almost mutually exclusive of other disease-defining genetic aberrations such as NPM1, biallelic mutated CEBPA, CBFB-MYH11, RUNX1-RUNX1T1, and PML-RARA. [126] [127] [128] In addition, RUNX1 mutations are characterized by a distinct gene expression pattern, 125, 127 and monoallelic germline mutations have been reported in rare cases of familial platelet disorder with predisposition to AML, 128 further supporting the idea of a separate disease entity. Therefore, the new provisional entity "AML with mutated RUNX1" (excluding cases with myelodysplasia-related changes)
was added to the current WHO classification. 6 Approximately twothirds of RUNX1 mutations are found in cytogenetically normal AML and have been associated with a very unfavorable prognosis in both young and elderly patients. 126, 127 Thus, RUNX1 was added to the adverse-risk group. 13 
| AML with TP53
The tumor protein p53 (TP53) encodes a transcription factor, which is involved in cell cycle arrest and apoptosis. 129 TP53 mutations occur in roughly 12% of AML patients, 130 predominantly in therapy-related or secondary AML as well as in elderly patients. 131 Moreover, TP53 alterations are found in roughly 70% of AML patients with a complex karyotype. 132 TP53 alterations predict for very low CR rates (less than 30%) and were shown to be an independent poor prognostic factor among the subgroup of AML with complex karyotype. 132 Interestingly, TP53 could be identified in hemat- alterations. 134 Although these responses were not durable, they resulted in OS rates that were similar to those among patients with AML who had an intermediate-risk cytogenetic profile and who also received serial 10-day courses of decitabine. 134 Recent data from 2 phase I trials suggest a high response rate after the combination therapy of venetoclax, a BCL2 inhibitor, with either decitabine, azacitidine (ClinicalTrials.gov identifier: NCT02203773), 135 or low-dose cytarabine 136 in newly diagnosed elderly (≥60 years) AML patients not eligible for intensive chemotherapy, a group in whom a high incidence of TP53 mutations would be suspected. After venetoclax and low-dose cytarabine, the overall response rate was 61% with 54% in patients achieving CR/CRi. 136 Venetoclax and low-dose cytarabine were shown to be active across a wide range of cytogenetic mutations and patient profiles (overall response rate: 70% in patients ≥75 years; 52% in secondary AML; 47% in patients with adverse karyotypes; 53% in patients previously treated with hypomethylating agents). The OS was estimated to be 79% at 6 months and 70% at 12 months, with the median not reached. 135 Based on these encouraging data, venetoclax received breakthrough designation by the 
| FLT3-mutated AML
Activating FLT3 mutations are one of the most frequently affected genetic abnormalities in AML and are present in about 30% of newly diagnosed patients. 3 As a member of the type III receptor tyros- Nevertheless, FLT3-TKDs can occur after treatment with FLT3 TKIs as a mechanism of resistance, thus implicating an adverse prognosis. 142 Besides cytogenetically normal AML, FLT3-ITD is frequently associated with t(6;9)(p23;q34) [58] [59] [60] as well as with t(15;17)(q22;q12) in APL. 3 The incidence of FLT3-ITD is associated with age: Whereas it can only rarely be found in children, its incidence is highest in young adults up to the age of 60 years and declines in the elderly. 143 Regarding specific ITD characteristics, the size of these duplications varies widely, typically ranging from 3 to over 100 base pairs (bps) with a median of 48 bps. 141 In addition, size and ITD insertion site in the FLT3 gene seem to be correlated in that the more 3' the insertion site within the FLT3 gene, the longer the ITD. 144 The impact of the size on outcome is still unclear with some publications stating no impact on outcome, 145, 146 whereas one publication found that short ITDs may impart an unfavorable outcome. 147 Nevertheless, most publications stated that longer ITDs correlate with lower CR rates and shorter OS and EFS. [148] [149] [150] In addition, the ITD insertion site within the FLT3 gene has been shown to be an important prognostic factor and was associated with an inferior prognosis. 144 About one-third of all FLT3-ITDs occur within the tyrosine kinase domain 1 (TKD1) of the FLT3 gene, in particular in the beta1-sheet. 144, 151 In cell culture analyses, a prototypic FLT3-ITD with insertion site in the β2-sheet of the TKD1 (FLT3-ITD627E) It should be noted, however, that no internationally standardized method of determining the allelic ratio has been established, and it is not routinely reported by many or even most commercial diagnostic laboratories. This is problematic for a practitioner attempting to managing these patients according to these ELN guidelines.
In addition, NUP98/NSD1 has been described to have a further independent prognostic impact in FLT3-ITD-mutated AML.
152,153
In 1421 patients from six Children Oncology Group/Southwest
Oncology Group trials, NUP98/NSD1 was detected in 15% ( improve the sensitivity of FLT3-ITD. 155 Nevertheless, this approach has limitations, since each FLT3-ITD mutation needs a clone-specific primer/probe set, which is time-consuming and may not be possible in every case. In addition, direct sequencing may be hampered due to low allelic ratio since the wild-type sequence is competitively amplified. Recently, another PCR-based assay for FLT3-ITD MRD was reported. 156, 157 This assay employed primers oriented in the opposite direction; hence, amplification occurred only if a FLT3-ITD was present. Again, this approach has limitations since short FLT3-ITDs (less than 30-40 bases) are not detected due to insufficient primer annealing space, which may apply to roughly 25% of all FLT3-ITD cases. Both approaches are therefore not ready to be implemented in clinical routine care. Next-generation sequencing (NGS) is potentially useful 158, 159 since it can identify clonal populations but generates complex data, which is still expensive and requires considerable expertise to interpret. Additionally, NGS gives only an estimate on the allelic ratio. In patients with a concurrent NPM1 mutation, however, MRD can be assessed by analysis of NPM1-mutated transcripts. In summary, FLT3 mutational testing should be mandatory in all AML patients at diagnosis as well as at relapse for prognostic purposes and for guiding therapeutic decisions. At present, it has little utility for MRD monitoring until different methodologies can be standardized.
Regarding postremission therapy in FLT3-ITD AML, allo-SCT has been shown to improve outcomes particular in patients with a high allelic ratio. [160] [161] [162] Nevertheless, recent studies indicate that AML patients with NPM1 mutation and low FLT3-ITD allelic ratio may have a more favorable prognosis and should therefore not routinely be assigned to allo-SCT. 103, 163, 164 In contrast, an ITD insertion site in the TKD1 remained an unfavorable prognostic factor regardless of the applied therapy. Nevertheless, a significant proportion of patients within the CALGB 10603/RATIFY trial still relapsed within the first two years, even in the midostaurin arm, 163 raising the question as to whether or not TKIs with higher FLT3 selectivity would be more efficient.
Currently, various other, more selective FLT3 inhibitors, such as quizartinib, 164, 165 crenolanib, 166 and gilteritinib, 167 
| ISOCITR ATE DEHYDROG ENA S E (IDH)
Mutations in IDH1 and IDH2 are detected in about 8% and 12% of patients with AML, respectively. 88 IDH1 mutations almost exclusively occur at R132 while IDH2 involve substitutions at R140 or R172. 169 These mutations tend to occur early in disease pathogenesis 170 and affect the active site of the IDH enzymes that exist in the cytoplasm (IDH1) and the mitochondria (IDH2 [190] [191] [192] [193] [194] Similarly, preclinical studies of DOT1L inhibition in acute leukemia associated with translocations involving the KMT2A gene have shown remarkable effectiveness. 195, 196 Translating these results to patients, however, has been more difficult. Inhibition of DOT1L with the small molecule inhibitor EPZ-5676 resulted in a CR in only two of 34 patients with a KMT2A rearrangement or partial tandem duplication. 197 In cell culture analysis using a DNMT3A-mutated cell line, inhibition of DOT1L resulted in inhibition of proliferation, induction of apoptosis, and terminal differentiation. 198 Again, the DOT1L inhibitor EPZ5676 was effective in a xenograft model as well as primary patient samples with DNMT3A-mutated AML, suggesting that DOT1L could be a therapeutic target. 198 
| LYS INE-S PECIFIC ME THYLTR AN S FER A S E 2 A (KMT2 A)
| DN MT3A M UTATI O N S
Awareness of the complexity of the leukemic genome has further been highlighted by the discovery of mutations in genes important for epigenetic regulation of gene transcription. DNA methyltransferase 3 alpha (DNMT3A) belongs to the family of DNA methyltransferase enzymes that catalyzes the addition of a methyl group to the cytosine of CpG dinucleotides, thereby regulating gene transcription.
DNMT3A mutations can be found in 15%-25% of AML patients, particularly in AML with normal cytogenetics, 5, [199] [200] [201] and are thought to be a "founder" mutation since they are present in early preleukemic hematopoietic stem cells. 202 Approximately 60% of all DNMT3A mutations affect residue R882, 5, 199 and seem to be age-dependent with a higher incidence in elderly patients. 203 Several studies evaluated the stability of DNMT3A mutations in paired diagnosis and relapse material. 93 In the largest analyses, Hou et al 204 At relapse, all DNMT3A-mutated patients who had available samples for serial study regained the same mutations, whereas all 103 patients without DNMT3A mutation at diagnosis remained DNMT3A negative at relapse. 204 Due to its high stability, the authors claimed DNMT3A mutations to be a potential marker for MRD monitoring. 
R E FE R E N C E S
